[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grail Inc (GRAL)

Grail Inc (GRAL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,693,041
  • Shares Outstanding, K 42,917
  • Annual Sales, $ 147,170 K
  • Annual Income, $ -408,350 K
  • EBIT $ -534 M
  • EBITDA $ -371 M
  • 60-Month Beta 3.03
  • Price/Sales 15.86
  • Price/Cash Flow N/A
  • Price/Book 0.82

Options Overview Details

View History
  • Implied Volatility 90.60% (-1.17%)
  • Historical Volatility 82.37%
  • IV Percentile 41%
  • IV Rank 49.09%
  • IV High 114.97% on 05/13/25
  • IV Low 67.09% on 09/04/25
  • Expected Move (DTE 8) 6.65 (10.73%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 97
  • Volume Avg (30-Day) 1,036
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 21,588
  • Open Int (30-Day) 23,008
  • Expected Range 55.29 to 68.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.94
  • Number of Estimates 3
  • High Estimate $-2.81
  • Low Estimate $-3.07
  • Prior Year $-3.18
  • Growth Rate Est. (year over year) +7.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.06 +41.27%
on 04/10/26
63.74 -2.34%
on 05/06/26
+13.09 (+26.64%)
since 04/07/26
3-Month
41.50 +49.99%
on 02/23/26
109.04 -42.92%
on 02/18/26
-37.83 (-37.80%)
since 02/06/26
52-Week
29.95 +107.83%
on 08/20/25
118.84 -47.62%
on 01/22/26
+27.53 (+79.33%)
since 05/07/25

Most Recent Stories

More News
GRAIL's Revenue Growth Continues, But the FDA Decision Everyone's Waiting For Remains Unresolved

Barchart Research What to Expect from GRAL Earnings GRAL Generated May 4, 2026 Current Price $55.66 EPS Estimate $$-3.00 Consensus Rating Moderate Buy Average Move 14.27% GRAIL's Revenue Growth Continues,...

GRAL : 64.62 (+2.98%)
Dear PayPal Stock Fans, Mark Your Calendars for May 5

PYPL stock has a very low valuation and multiple, powerful, potential catalysts. Here's what else to know ahead of its Q1 earnings.

PYPL : 46.94 (+1.45%)
SNDK : 1,359.37 (-3.59%)
GRAL : 64.62 (+2.98%)
HPQ : 21.32 (-0.42%)
GEV : 1,094.99 (-2.14%)
WMT : 129.59 (-0.38%)
GRAIL to Present at the BofA Securities 2026 Health Care Conference

MENLO PARK, Calif. , April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...

GRAL : 64.62 (+2.98%)
GRAIL to Announce First Quarter 2026 Financial Results

MENLO PARK, Calif. , April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...

GRAL : 64.62 (+2.98%)
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation

GRAL : 64.62 (+2.98%)
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk

GRAL : 64.62 (+2.98%)
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal

GRAL : 64.62 (+2.98%)
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GRAIL, Inc. (“GRAIL” or “the Company”) (NASDAQ:...

GRAL : 64.62 (+2.98%)
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

Partnership expands access to breakthrough blood-based cancer screening into Superpower's comprehensive health check and personalized plans.

GRAL : 64.62 (+2.98%)
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk

GRAL : 64.62 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.

See More

Key Turning Points

3rd Resistance Point 77.38
2nd Resistance Point 70.56
1st Resistance Point 66.65
Last Price 64.62
1st Support Level 55.93
2nd Support Level 49.11
3rd Support Level 45.20

See More

52-Week High 118.84
Fibonacci 61.8% 84.88
Fibonacci 50% 74.39
Last Price 64.62
Fibonacci 38.2% 63.91
52-Week Low 29.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.